Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →A grade PMID 42260111
View analysis →In a multicenter, nonrandomized phase 1/2 trial, first-line avelumab plus methotrexate produced serum hCG normalization in 96.2% of 26 assessable patients with low-risk gestational trophoblastic tumors, with manageable reported toxicity, no relapses at a median 41-month follow-up, and pregnancies in 13 of 14 patients who intended pregnancy.
The trial provides preliminary human evidence that adding PD-L1 blockade to methotrexate can achieve durable hCG normalization while preserving fertility in low-risk GTT; it is an inference, not yet comparative evidence, that this combination improves cure rates or is especially beneficial for patients at higher risk of methotrexate resistance.
In a multicentre, single-arm phase 1/2 trial of 55 medically fit adults with relapsed or refractory acute myeloid leukaemia, venetoclax plus cytarabine and mitoxantrone produced a 75% composite complete remission rate, with febrile neutropenia and serious infections prominent and four potentially treatment-related deaths reported.
The trial provides clinical evidence that adding venetoclax to intensive cytarabine–mitoxantrone salvage therapy has activity in fit adults with relapsed or refractory AML; it is reasonable but still inferential to hypothesize that this regimen could improve remission induction and enable more patients to proceed to allogeneic HCT, because efficacy was not compared with a control group and pediatric applicability was not tested.
In a prospective phase II study of 68 patients with resectable head and neck squamous cell carcinoma receiving perioperative pembrolizumab, a genome-wide cfDNA end-motif entropy metric distinguished immunotherapy responders from nonresponders and was associated with disease-free survival.
The study provides evidence that longitudinal regional cfDNA motif diversity correlates with pembrolizumab response; it supports, but does not establish, the hypothesis that rMDS could enable minimally invasive response monitoring or risk stratification after prospective external validation.
In a 39-patient, open-label, single-arm phase 2 study of high-risk neuroblastoma, racotumomab induced anti-mouse and NeuGc-directed immune responses, including ADCC in a minority of patients, with no serious treatment-related adverse events and an exploratory association between IgM response and progression-free survival.
The study provides evidence that racotumomab can elicit NeuGc glycoconjugate-directed antibodies and occasional ADCC in children with high-risk neuroblastoma; it supports, but does not establish, the hypothesis that vaccine-induced immunity against tumor-associated NeuGcGM3 could help control residual disease, particularly in immunologic responders.
In a randomized 35-patient trial of children with newly diagnosed high-risk neuroblastoma and non-progressive disease after intensive initial therapy, dinutuximab alternating with G-CSF/teceleukin produced survival estimates interpreted as comparable to the ANBL0032-based GM-CSF/aldesleukin/isotretinoin regimen, without an obvious difference in frequently recorded grade 3/4 toxicities.
The trial provides preliminary clinical evidence that G-CSF/teceleukin may serve as an alternative cytokine regimen with dinutuximab where GM-CSF, aldesleukin, and isotretinoin are unavailable; equivalence or noninferiority remains an inference requiring confirmation in a larger phase III trial.
In a 650-patient randomized phase III trial of previously untreated, low-risk DLBCL in patients aged 18-80 years, PET-guided reduction to four R-CHOP cycles for early PET-negative patients was noninferior to six cycles and was associated with fewer grade ≥3 and serious adverse events.
The trial directly supports, in the studied adult and young-adult low-risk DLBCL population, the hypothesis that PET negativity after two R-CHOP cycles can identify patients who may receive four rather than six cycles without compromising 3-year progression-free survival while reducing toxicity; application to children or broader-risk DLBCL populations remains an inference not tested by this record.
The study reports that linsitinib or selective FECH inhibition lowers heme and energy production in chronically antigen-activated GD2.CAR T cells, shifts them toward a less activated/exhausted and more central-memory phenotype, and that linsitinib enhances CAR T-cell antitumor activity in linsitinib-sensitive neuroblastoma cell lines.
The supplied evidence supports FECH-dependent heme metabolism as a modulator of GD2.CAR T-cell phenotype and bioenergetics; it remains an inference requiring further testing that transient or selective FECH inhibition could improve CAR T-cell persistence and therapeutic efficacy in patients with neuroblastoma without impairing expansion, function, or safety.
This phase 1/2 TACL study of 24 pediatric patients with relapsed/refractory ALL found that ixazomib could be combined with relapse chemotherapy at an RP2D of 2 mg/m², with reported acceptable safety, a 67% complete response rate among evaluable patients, and flow MRD negativity in 9 of 14 responders.
The study provides early clinical evidence that adding the oral proteasome inhibitor ixazomib to established relapse chemotherapy is feasible and may have antileukemic activity in pediatric relapsed/refractory ALL; whether ixazomib improves response durability or survival beyond chemotherapy alone remains an untested inference requiring controlled trials.
In this global phase 3 trial of 899 randomized adults with previously untreated high-risk DLBCL or HGBL, adding tafasitamab and lenalidomide to R-CHOP improved progression-free survival but increased grade 3 or higher and fatal treatment-emergent adverse events, while overall-survival results remained immature.
The trial provides evidence that adding anti-CD19 tafasitamab and lenalidomide to first-line R-CHOP can reduce the risk of progression or death in high-risk adult DLBCL or HGBL; it remains an inference that this benefit will translate into longer overall survival or a favorable net clinical benefit, and the supplied record does not establish efficacy or safety in pediatric patients.
In a temozolomide-resistant Th-MYCN neuroblastoma mouse model and derived allografts, molecular profiling identified CDK2-pathway deregulation, and fadraciclib treatment produced significant tumor responses and an overall-survival benefit.
The supplied preclinical evidence supports activity of the CDK2/9 inhibitor fadraciclib in temozolomide-resistant neuroblastoma; it is reasonable, but not yet clinically demonstrated, to hypothesize that CDK2/9 inhibition could overcome or exploit resistance-associated dependencies in relapsed neuroblastoma and improve responses to temozolomide-based therapy.
This review summarizes genomic targets and emerging therapies in T-ALL, including pediatric/AYA front-line benefit reported with nelarabine, an approximately 80% response rate for daratumumab plus chemotherapy, and response rates above 90% in early-phase CAR-T trials for relapsed/refractory disease.
The supplied record reports encouraging clinical activity for nelarabine, daratumumab-based therapy, and early CAR-T approaches; it supports the inference that genomically informed targeting and immunotherapy could improve front-line or salvage outcomes in T-ALL, but comparative benefit, durability, safety, and appropriate patient selection remain unestablished for most emerging approaches.
In a single-center, open-label randomized trial of 127 children with ALL receiving high-dose methotrexate, ice-cold saline oral cryotherapy reduced day-14 any-grade and grade ≥II oral mucositis versus standard oral care, without shortening mucositis duration or causing reported serious cryotherapy-related adverse events.
The trial provides evidence that oral cryotherapy can reduce the incidence and severity of high-dose methotrexate-associated oral mucositis in pediatric ALL; it is reasonable but still inferential to hypothesize that this simple supportive-care intervention could reduce mucositis-related burden in routine care, pending confirmatory multicenter, intention-to-treat studies and further evaluation across age and methotrexate-dose groups.
